These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38962540)

  • 41. A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.
    Jo H; Hong J; Kim H; Kim HR; Kwon GY; Kang KA; Park SY; Kim CK; Park BK; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH
    Front Oncol; 2022; 12():874385. PubMed ID: 35574412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Impact of Proton Pump Inhibitors on the Efficacy of Immune Checkpoint Inhibitor Combinations in Patients with HBV-Associated Advanced Hepatocellular Carcinoma.
    Wang N; Xu Y; Yang G; Chen H; Wang X; Fu J; Li L; Pan X
    J Hepatocell Carcinoma; 2024; 11():1311-1321. PubMed ID: 38979082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
    Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N
    Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
    Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
    JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of concurrent medications on the outcome of immunotherapy in non-small cell lung carcinoma.
    Yamada J; Fukui T; Yatani A; Mimura C; Fukuda K; Hazama D; Katsurada N; Nagano T; Yamamoto M; Tachihara M
    Thorac Cancer; 2024 May; 15(15):1228-1236. PubMed ID: 38622898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.
    Martini DJ; Olsen TA; Goyal S; Liu Y; Evans ST; Hitron EE; Russler GA; Yantorni L; Caulfield S; Brown JT; Goldman JM; Nazha B; Carthon BC; Harris WB; Kucuk O; Master VA; Bilen MA
    J Immunother Precis Oncol; 2022 Aug; 5(3):52-57. PubMed ID: 36034580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
    Zhuang TZ; Case K; Olsen TA; Brown JT; Carthon BC; Kucuk O; Goldman J; Harris W; Bilen MA; Nazha B
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740533
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
    Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
    J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
    Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
    Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors.
    Elkrief A; El Raichani L; Richard C; Messaoudene M; Belkaid W; Malo J; Belanger K; Miller W; Jamal R; Letarte N; Wong P; Routy B
    Oncoimmunology; 2019; 8(4):e1568812. PubMed ID: 30906663
    [No Abstract]   [Full Text] [Related]  

  • 56. REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.
    Vauchier C; Auclin E; Barthélémy P; Carril-Ajuria L; Ryckewaert T; Borchiellini D; Castel-Ajgal Z; Bennamoun M; Campedel L; Thiery-Vuillemin A; Coquan E; Crouzet L; Berdah JF; Chevreau C; Ratta R; Fléchon A; Lefort F; Albiges L; Gross-Goupil M; Vano YA; Thibault C; Oudard S
    J Oncol; 2022; 2022():3449660. PubMed ID: 35222642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study.
    Yip W; Ghoreifi A; Gerald T; Lee R; Howard J; Asghar A; Khanna A; Cai J; Aron M; Gill I; Thompson RH; Uzzo R; Margulis V; Singla N; Djaladat H
    Eur Urol Oncol; 2023 Dec; 6(6):604-610. PubMed ID: 37005212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study.
    Kim H; Lee JE; Hong SH; Lee MA; Kang JH; Kim IH
    BMC Cancer; 2019 Nov; 19(1):1100. PubMed ID: 31718585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
    Homicsko K; Dummer R; Hoeller C; Wolchok JD; Hodi FS; Larkin J; Ascierto PA; Atkinson V; Robert C; Postow MA; Re S; Paulucci D; Dobler D; Michielin O
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565428
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
    Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
    Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.